Kelly Michael Aaron 4

What Happened
Kelly Michael Aaron, a director of Amicus Therapeutics (FOLD), reported multiple dispositions on 2026-04-27 in connection with the company's acquisition by BioMarin. He disposed of 72,468 shares of common stock to the issuer at $14.50 per share (proceeds shown as $1,050,786). In addition, several derivative positions (stock options) covering 36,111; 45,423; 30,474; 42,467; and 74,872 shares were cancelled/converted and reported as dispositions (transaction amounts shown as N/A on the Form 4). Footnotes state the cancelled options were fully vested and converted into cash payments equal to the excess of $14.50 per share over each option's exercise price multiplied by the number of shares covered.

Key Details

• Transaction date: 2026-04-27 (filed same day).
• Disposed common shares: 72,468 at $14.50 each — reported proceeds $1,050,786.
• Derivative dispositions (options): 36,111; 45,423; 30,474; 42,467; 74,872 — cash settlement amounts not specified on the Form 4.
• Footnotes: 52,054 common shares + 20,414 RSUs vested and were included in the 72,468 share disposition; each option vested/was vested in full and was cancelled for a cash payment tied to $14.50 per share.
• Shares owned after the transactions: not specified in the Form 4.
• Timeliness: filing date equals transaction date — appears timely.

Context
These transactions were part of the merger consideration paid by BioMarin Pharmaceutical Inc.; the common shares/vested RSUs were turned in to the issuer and several stock options were cashed out rather than converted into continuing equity. The Form 4 reports the disclosed share sale proceeds ($1.05M) but does not list the cash amounts received for the option cancellations, so total proceeds to the insider are not fully shown on the Form 4.